The purpose of this study is to explore etentamig (ABBV-383) and its safety and tolerability as a monotherapy or combined with other anti-myeloma agents. This study aims to determine the safest dose of etentamig and if it produces meaningful anti-myeloma activity for participant with multiple myeloma (MM).
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Eben Lichtman
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Multiple Myeloma)
25-0637